

Stanford

Ming Li (Estella) Chen

Postdoctoral Scholar, Cardiovascular Medicine

Bio

BIO

I am an MD from Chung Shan Medical University, Taiwan. Before coming to Stanford, I obtained my MS degree in epidemiology at Harvard T.H. Chan School of Public Health, Boston, MA, where I completed graduate training in clinical, pharmacologic, and genetic epidemiology, and pursued advanced skills in biostatistics and causal inference.

My past research focused on real-world epidemiology studies using patient registries and national health insurance databases to elucidate the predictors or risk factors of immunologic diseases. For my graduate study, I conducted pharmacoepidemiology studies using electronic health record (EHR) data to elucidate the predictors of anti-drug antibodies development and its correlation to autoimmunity, to identify the generation of immunogenicity that may impact the effectiveness of monoclonal antibody therapies in individuals with autoimmune diseases. I gained experience in genetic data manipulation to investigate polymorphisms in response to monoclonal antibody therapies in asthma patients.

At Stanford, I am involved in research on the identification of molecular determinants of cardiometabolic diseases.

PROFESSIONAL EDUCATION

- Doctor of Medicine, Chung Shan Medical & Dental College (2021)
- Master of Science, Harvard University (2023)
- Master of Science, Harvard T.H. Chan School of Public Health, Boston, MA , Epidemiology (2023)
- Doctor of Medicine, Chung Shan Medical University, Taichung, Taiwan , Medicine (2021)

STANFORD ADVISORS

- Themistocles Assimes, Postdoctoral Faculty Sponsor

LINKS

- My Google Scholar: https://scholar.google.com/citations?user=G28Bp_oAAAAJ&hl=en&oi=sra
- My LinkedIn: <https://www.linkedin.com/in/ming-li-estella-chen>

Publications

PUBLICATIONS

- **Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE*
Chen, M., Nopsopon, T., Akenroye, A.
2023; 11 (5): 1475-+
- **Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Nopsopon, T., Lassiter, G., Chen, M., Alexander, C., Keet, C., Hong, H., Akenroye, A.

